Gustave Roussy Cancer Profiling (STING)

February 5, 2026 updated by: Gustave Roussy, Cancer Campus, Grand Paris
The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

STING is a biology driven, multicenter study designed to identify actionable molecular alterations in cancer patients and to explore mechanisms of sensitivity and resistance to anti-cancer treatment

  • In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling
  • Patients included in the STING study and for whom a targetable genomic alteration had been identified might be subsequently included in a clinical trial running at Gustave Roussy or another participating center.

Study Type

Interventional

Enrollment (Estimated)

20000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Le Plessis-Robinson, France, 92350
      • Paris, France, 75014
        • Not yet recruiting
        • Hôpital Saint-Joseph
        • Contact:
      • Suresnes, France, 92150
        • Not yet recruiting
        • Hopital Foch
        • Contact:
    • Val de Marne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Histology: solid malignant tumor or hematological malignancy.
  3. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)
  4. Voluntary signed and dated written informed consent prior to any study specific procedure.

Exclusion Criteria:

  1. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol
  2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
  3. Pregnant or breast-feeding women
  4. Minors (Age < 18 years)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: solid tumor or hematological malignancy
Procedure: Biopsy
Blood and tumor samples for Genetic Profiling research

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients presenting at least one targetable genomic alteration
Time Frame: 2 months after the last enrollment
Number of patients presenting at least one targetable genomic alteration
2 months after the last enrollment
Proportion of patients presenting at least one targetable genomic alteration
Time Frame: 2 months after the last enrollment
Proportion of patients presenting at least one targetable genomic alteration
2 months after the last enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of molecular profiling information including utilization of information for standard regimens or clinical trials of molecularly targeted therapies
Time Frame: 2 months after the last enrollment
For a patient with molecular results available utilization of molecular profiling information is defined as Inclusion in a clinical trial assessing a drug matched to the molecular alteration And/or Treatment with an approved drug matched with the molecular alteration
2 months after the last enrollment
Objective response rate
Time Frame: 24 months post treatment after the last enrollment
24 months post treatment after the last enrollment
Progression-free survival
Time Frame: 24 months post treatment after the last enrollment
24 months post treatment after the last enrollment
Overall survival
Time Frame: 24 months post treatment after the last enrollment
24 months post treatment after the last enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Investigators

  • Principal Investigator: Antoine Italiano, MD PhD, Gustave Roussy, Cancer Campus, Grand Paris

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 10, 2021

Primary Completion (Estimated)

May 10, 2033

Study Completion (Estimated)

May 10, 2033

Study Registration Dates

First Submitted

June 1, 2021

First Submitted That Met QC Criteria

June 18, 2021

First Posted (Actual)

June 21, 2021

Study Record Updates

Last Update Posted (Actual)

February 6, 2026

Last Update Submitted That Met QC Criteria

February 5, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-A03547-32
  • 2020/3196 (Other Identifier: CSET number (Gustave Roussy ID))

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe